Infectious Disease

CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.

VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.

Pharmacists can reduce COVID-19 vaccine hesitancy through honest, nonjudgmental communication and by using every patient touchpoint as an opportunity to offer vaccination.

A study author explains how pharmacists can help close vaccination gaps in rural communities and what lower ICU admission rates among vaccinated older adults may mean.

Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.

Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.

In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.

The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.

VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.

Emergency and ICU pharmacists would be most likely to see pneumonic plague. An expert reviews first-line agents, alternatives, and postexposure prophylaxis.

The FDA approval of pritelivir offers an oral treatment for refractory HSV lesions in immunocompromised adults, with drug interactions creating an important role for pharmacists.

A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague, and which antibiotics the CDC recommends.

Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.

Age is the leading factor in influenza vaccine selection, and vaccination remains effective well beyond the ideal September-to-October window.

Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.

Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.

Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.

Marie-Claire Seeley, PhD, MNurs, RN, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.

Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.

A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.

Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.

Most patients screened by a hospital pharmacist–led transitions-of-care service had unmet pneumococcal and other vaccine needs, and most accepted vaccination when offered.

The data help pharmacists predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.

CDC-recommended adult vaccination programs for pneumococcal disease, RSV, influenza, and COVID-19 prevent over 182,000 deaths and generate up to $12 in societal value for every $1 spent.

Pharmacists play a key role in guiding age- and risk-based vaccination decisions to protect against invasive and noninvasive disease.